But although that is true, the real reason ethanol has become the preferred green substitute for petrol is that people know how to make it—that, and the subsidies now available to America’s maize farmers to produce the necessary feedstock. Yet such things do not stop ethanol from being a lousy fuel. To solve that, the biotechnologists argue, you need to make a better fuel that is equally green. Which is what they are trying to do.
Designer petrol
The first step on the road has been butanol. This is also a type of alcohol that can be made by fermenting sugar (though the fermentation is done by a species of bacterium rather than by yeast), and it has some advantages over ethanol. It has more carbon atoms in its molecules (four, instead of two), which means more energy per litre—though it is still only 85% as rich as petrol. It also has a lower tendency to absorb water from the atmosphere.
A joint venture between DuPont, a large American chemical company, and BP, a British energy firm, has worked out how to industrialise the process of making biobutanol, as the chemical is commonly known when it is the product of fermentation. Although BP plans to start selling the stuff in the next few weeks (mixed with petrol, to start with), the truth is that butanol is not all that much better than ethanol. The interesting activity is elsewhere.
One route might be to go for yet-larger (and thus energy-richer) alcohol molecules. Any simple alcohol is composed of a number of carbon and hydrogen atoms (like a hydrocarbon such as petrol) together with a single oxygen atom. In practice, this game of topping up the carbon content to make a better fuel stops with octanol (eight carbon atoms) as anything bigger tends to freeze at temperatures that might be encountered in winter. But living things are familiar with alcohols. Their enzymes are geared up to cope with them. This makes the biotechnologists’ task that much easier.
The idea of engineering enzymes to make octanol was what first brought Codexis, a small biotechnology firm based in Redwood City, California, into the field. Codexis’s technology works with pharmaceutical precision—indeed, one of its main commercial products is the enzyme system for making the chemical precursor to Lipitor, a cholesterol-lowering drug that is marketed by Pfizer. Codexis controls most of the important patents for what is known as molecular evolution. This designs enzymes in the way that normal evolution designs organisms. It creates lots of variations on a theme, throws away the ones it does not want, and shuffles the rest in a process akin to sex. It then repeats the process on the survivors until something useful emerges—though, unlike natural evolution, there is a bit of intelligent design in the process, too. The result, according to Codexis’s boss, Alan Shaw, is enzymes that can perform chemical transformations unknown in nature.
Dr Shaw, however, is no longer so interested in octanol as a biofuel. Like two other, nearby firms, he is now focusing Codexis’s attention on molecules even more chemically similar to petrol. The twist that Codexis brings is that unlike petrol, of which each batch from the refinery is chemically different from the others (because the crude oil from which it is derived is an arbitrary mixture of hydrocarbon molecules), biopetrol could be turned out exactly the same, again and again, and thus designed to have the optimal mixture of properties required of a motor fuel.
Exactly which molecules Codexis is most interested in these days, Dr Shaw is not yet willing to say. But Amyris Biotechnologies, which is also based in California, in Emeryville, and which also started by dabbling in drugs (in its case an antimalarial medicine called artemisinin), is slightly more forthcoming. Under the guidance of its founder Jay Keasling, it has been working on a type of isoprenoid (a class of chemicals that include rubber).
Unlike Codexis, which deals in purified enzymes, Amyris employs a technique called synthetic biology, which turns living organisms into chemical reactors by assembling novel biochemical pathways within them. Dr Keasling and his colleagues scour the world for suitable enzymes, tweak them to make them work better, then sew the genes for the tweaked enzymes into a bacterium that thus turns out the desired product. That was how they produced artemisinin, which is also an isoprenoid.
Isoprenoids have the advantage that, like alcohols, they are part of the natural biochemistry of many organisms. Enzymes to handle them are thus easy to come by. They have the additional advantage that some are pure hydrocarbons, like petrol. With a little judicious searching, Amyris thinks it has come up with isoprenoids that have the right characteristics to substitute for petrol.
The third Californian firm in the business, LS9 of San Carlos, is cutting to the chase. If petrol is what is wanted, petrol is what will be delivered. And diesel, too, although in this case the product is actually biodiesel, which is in some ways superior to the petroleum-based stuff.
LS9 also uses synthetic biology, but it has concentrated on controlling the pathways that make fatty acids. Like alcohols, fatty acids are molecules that have lots of hydrogen and carbon atoms, and a small amount of oxygen (in their case two oxygen atoms, rather than one). Plant oils consist of fatty acids combined with glycerol—and these fatty acids (for example, those from palm oil) are the main raw material for the biodiesel already sold today.
LS9 has used its technology to turn microbes into factories for fatty acids containing between eight and 20 carbon atoms—the optimal number for biodiesel. But it also plans to make what it calls “biocrude”. In this case the fatty acids would have 18-30 carbon atoms, and the final stage of the synthetic pathway would clip off the oxygen atoms to create pure hydrocarbons. This biocrude could be fed directly into existing oil refineries, without any need to modify them.
These firms, however, have one other competitor. His name is Craig Venter. Dr Venter, a veteran of biotechnological scraps ranging from gene patenting to the private human-genome project, has been interested in bioenergy for a long time. To start with, it was hydrogen that caught his eye, then methane—both of which are natural bacterial products. But now that eye is shifting towards liquid fuels. His company, modestly named Synthetic Genomics (and based, unlike the others, on the east side of America, in Rockville, Maryland), is reluctant to discuss details, but Dr Venter, too, is taken with the pharmaceutical analogy. Indeed, he goes as far as to posit the idea of clinical trials for biofuels—presumably pitting one against another, perhaps with petroleum-based products acting as the control, and without the drivers knowing which was which.
Whether biofuels will ever be competitive with fossil fuels remains to be seen. That will depend on a mixture of economics and politics. But the political rush to back ethanol, just because it is green and people have heard of it, is a mistake. Let a thousand flowers bloom, and see which one wins Dr Venter’s Grand Prix.
